Skip to content Skip to footer
Subscribe Now
NEWS

Amplitude Therapeutics and Eli Lilly Partner to Develop Trans-Amplifying RNA Vaccines for Infectious Diseases

Shots: Amplitude and Lilly entered into a strategic research collaboration and licensing agreement to discover and develop trans-amplifying RNA (taRNA) vaccine candidates for infectious diseases. Lilly retains the option to add up to two additional infectious disease targets. The collaboration combines Amplitude’s proprietary taRNA platform with Lilly’s global development, manufacturing, regulatory, and commercialisation capabilities. Amplitude…
August 20, 2026

Read more

NEWS

Lupin and Tenpoint Therapeutics Partner to Commercialize YUVEZZI in Key European Markets for Presbyopia

Shots: Lupin, through its wholly owned subsidiary VISUfarma B.V., entered into an exclusive licensing agreement with Visus Therapeutics, a wholly owned subsidiary of Tenpoint Therapeutics, to commercialize YUVEZZI (carbachol and brimonidine tartrate ophthalmic solution) 2.75%/0.1% for presbyopia in the European Union, United Kingdom, Switzerland, Norway, and Iceland Under the agreement, VISUfarma will hold exclusive rights…
August 20, 2026

Read more

NEWS

Tolerance Bio Licenses Efineptakin Alfa from NeoImmuneTech to Advance Thymic Function and Immune Resilience Programs

Shots: Tolerance Bio entered into an exclusive license agreement with NeoImmuneTech for the development and commercialization of efineptakin alfa (NT-I7), for certain thymus-related indications in the Americas and Europe. The company also plans to initiate P-II studies evaluating the therapy for enhancement of thymic function Under the agreement, Tolerance Bio will advance efineptakin alfa alongside…
August 20, 2026

Read more

NEWS

Ultragenyx Receives FDA Accelerated Approval for GENGLYCOS Gene Therapy to Treat the Underlying Cause of GSDIa

Shots: Ultragenyx reported the US FDA accelerated approval to GENGLYCOS (pariglasgene brecaparvovec-opnr; DTX401) for adults and pediatric patients (≥8yrs., n=46) with glycogen storage disease type Ia (GSDIa) The approval was supported by the P-III (GlucoGene) study, in which GENGLYCOS (n=20) demonstrated a statistically significant reduction in cornstarch requirements at 48wks. vs PBO (n=24) (p<0.001). The…
August 20, 2026

Read more

NEWS

NORROY BIOSCIENCE Receives FDA Breakthrough Therapy and Fast Track Designations for 68Ga-NYM096 in Kidney Cancer Imaging

Shots: NORROY BIOSCIENCE reported that the FDA has granted Breakthrough Therapy and FTD to 68Ga-NYM096, a radiopharmaceutical imaging agent targeting CAIX for PET imaging of clear cell renal cell carcinoma (ccRCC) 68Ga-NYM096 is being developed as a non-invasive PET imaging agent to characterize indeterminate renal masses identified by CT or MRI and help differentiate ccRCC…
August 20, 2026

Read more

TOP 20

Top 20 Generic Pharma Companies of 2026 

Shots:   Sandoz, Sun Pharma, and Shanghai Fosun Pharma emerged as the leading generic pharmaceutical companies in 2026, with 2025 revenues of $11.08B, $6.55B, and $5.92B, respectively. Strong demand for biosimilars, continued portfolio expansion, new product launches, and broader access to affordable medicines supported growth across the leading companies The global generics landscape continues to evolve…
August 14, 2026

Read more

TOP 20

Top 20 R&D Spending Biopharma Companies of 2026 

Shots:   Merck & Co., Roche, and Johnson & Johnson emerged as the leading pharmaceutical companies by R&D expenditure in 2025, investing $15.78B, $15.49B, and $14.66B, respectively. Continued investments in late-stage clinical programs, pipeline expansion, advanced technologies, and strategic business development reinforced their commitment to driving pharmaceutical innovation  Global biopharmaceutical R&D investment continues to accelerate as…
July 31, 2026

Read more

Amgen
NEWS

CHMP Recommends Expanded EU Indication for Amgen’s Repatha to Reduce First Heart Attack and Stroke Risk In Adults

Shots: Amgen announced that the CHMP issued a positive opinion recommending an expanded indication for Repatha (evolocumab) to reduce cardiovascular risk in adults with established or high risk for atherosclerotic cardiovascular disease by lowering LDL-C levels, alongside correction of other risk factors The recommendation is supported by the P-III (VESALIUS-CV) study involving  ≥12,000 pts., Repatha…
July 31, 2026

Read more

Pfizer New
NEWS

Pfizer Reports Positive P-III Results for LITFULO in Nonsegmental Vitiligo (NSV)

Shots: Pfizer reported positive topline results from the pivotal P-III TRANQUILLO and TRANQUILLO 2 studies evaluating LITFULO (ritlecitinib) in pts. with NSV. Both studies (n=2,174 pts) met their co-primary endpoints, demonstrating statistically significant improvements in facial and total body repigmentation vs. PBO at 52 wks. across 271 sites globally TRANQUILLO (n=607, ≥12yrs.) evaluated 50mg LITFULO and TRANQUILLO…
July 31, 2026

Read more

NEWS

NIPRO Receives FDA 510(k) Clearance for ELISIO-HX Dialyzer for Expanded Hemodialysis in the US

Shots: NIPRO CORPORATION received US FDA 510(k) clearance for its ELISIO-HX dialyzer, enabling the US commercialization of HDs (Hemodialysis powered by super high-flux membrane). The clearance became effective on July 28, 2026 ELISIO-HX features NIPRO’s proprietary super high-flux membrane technology, designed to enhance the removal of larger middle-molecule uremic toxins while maintaining albumin retention. The…
July 31, 2026

Read more

Load more